Predictive Oncology Inc. Files 8-K

TL;DR

Predictive Oncology (formerly Skyline Medical, Precision Therapeutics) filed an 8-K on 11/20/25.

AI Summary

Predictive Oncology Inc. filed an 8-K on November 20, 2025, reporting "Other Events." The filing indicates the company was formerly known as Skyline Medical Inc. until August 7, 2013, and Precision Therapeutics Inc. until March 14, 2018. The company is incorporated in Delaware and headquartered in Pittsburgh, PA.

Why It Matters

This filing provides historical context on the company's name changes, which can be important for investors tracking its evolution and corporate identity.

Risk Assessment

Risk Level: low — The filing is primarily informational, detailing past company name changes and standard corporate reporting, posing no immediate new risks.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• Skyline Medical Inc. (company) — Former Company Name
• Precision Therapeutics Inc. (company) — Former Company Name
• November 20, 2025 (date) — Date of Report
• Pittsburgh, PA (location) — Company Headquarters

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market
• $343.5 m — received an aggregate of approximately $343.5 million, including approximately $50.8 mi
• $50.8 million — $343.5 million, including approximately $50.8 million in cash and approximately $292.7 millio
• $292.7 million — $50.8 million in cash and approximately $292.7 million in notional value of in-kind contributi
• $173.3 million — ing a discounted value of approximately $173.3 million. As of the date of this Current Report
• $2.5 million — ts stockholders' equity is in excess of $2.5 million following the closing of the PIPE trans

Filing Documents

• f8k_112025.htm (8-K) — 23KB
• 0001171843-25-007488.txt ( ) — 184KB
• poai-20251120.xsd (EX-101.SCH) — 3KB
• poai-20251120_lab.xml (EX-101.LAB) — 33KB
• poai-20251120_pre.xml (EX-101.PRE) — 22KB
• f8k_112025_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. As previously reported, on November 20, 2024, Predictive Oncology Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). As also previously reported, on October 7, 2025, the Company closed two private investment in public equity ("PIPE") transactions and received an aggregate of approximately $343.5 million, including approximately $50.8 million in cash and approximately $292.7 million in notional value of in-kind contributions of certain crypto assets, representing a discounted value of approximately $173.3 million. As of the date of this Current Report on Form 8-K, the Company believes it has regained compliance with the Stockholders' Equity Requirement, as its stockholders' equity is in excess of $2.5 million following the closing of the PIPE transactions. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: November 20, 2025 By: /s/ Josh Blacher Josh Blacher Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR